TY  - JOUR
T1  - PRogression from precursor disease to multiple myeloma—reply
AU  - Landgren O, Waxman A, Korde N
Y1  - 2011/03/16
N1  - 10.1001/jama.2011.302
JO  - JAMA
SP  - 1094
EP  - 1094
VL  - 305
IS  - 11
N2  - 
An important feature of the 2010 IMWG guidelines is the introduction of low-risk, intermediate-risk, and high-risk categories of MGUS and smoldering myeloma.1 These categories are based on standard clinical markers. While the prior 2003 guidelines recommended annual follow-up for all patients with MGUS,2 the 2010 guidelines suggest that low-risk MGUS patients (approximately 40% of all patients) with less than a 5% risk of progression at 20 years of follow-up should be assessed with serum protein electrophoresis at 6 months.1 If stable, they can be followed up every 2 to 3 years or when symptoms suggest plasma cell malignancy.1

SN  - 0098-7484
M3  - doi: 10.1001/jama.2011.302
UR  - http://dx.doi.org/10.1001/jama.2011.302
ER  -